Page 20 - Breakthrough Device News Today

Diadem Builds Out Executive Team As It Prepares for Commercialization of Its AlzoSure® Predict Prognostic Test for Alzheimer's Disease - read this article along with other careers information, tips and advice on BioSpace

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 28, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced an update on the COSIRA-II

Business Scoop provides news and views on Business and Markets from New Zealand

/PRNewswire/ -- Diadem SpA, (or Diadem US, Inc.) a company developing the first blood-based test for the early prediction of progression to Alzheimers disease...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 18, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that European Heart

The U.S. Food and Drug Administration (FDA) recently issued the draft guidance “Select Updates for the Breakthrough Devices Program Guidance: Reducing Disparities in Health and Health...

MediBeacon approaching completion of Phase 3 study focused on kidney disease; Has submitted three of five required PMA modules needed for FDA approval ST. LOUIS, Nov. 16, 2022 /PRNewswire/

The FDA has developed draft guidance to propose select updates to the FDA guidance document, “Breakthrough Devices Program.”

/PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life...

On October 21st, the U.S. Food and Drug Administration (FDA) released a draft guidance that, if finalized, will update the agency's 2018 guidance on its Breakthrough Devices Program...